South Korea Alleges Google Abused Android App Store Dominance, Eyes Major Fine 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Microsoft Reportedly Plans New Job Cuts Across Sales, Consulting, and Xbox 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Pedro Sanchez’s Wife Ordered to Stand Trial in Spain Corruption Case 
Morgan Stanley Names BAE Systems Top European Defence Stock Despite Lower Price Target 
Nvidia Stock Rises as SemiAnalysis Sees AI Data Center Revenue Beating Wall Street Forecasts 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
Trump Reports $1.4 Billion in Crypto Income as Digital Assets Become Top Wealth Source 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
US Supreme Court Strikes Down Hawaii Gun Carry Law on Private Property 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
Two major pharmaceutical companies, Danco Laboratories and GenBioPro, have petitioned the U.S. Supreme Court to restore nationwide mail-order access to mifepristone, a widely used abortion pill. The emergency request comes after a federal appeals court temporarily blocked remote distribution of the drug, creating uncertainty for patients and healthcare providers across the United States.
The ruling from the 5th U.S. Circuit Court of Appeals in New Orleans significantly limits access to mifepristone, particularly affecting women in states with strict abortion bans. This decision marks a critical moment in ongoing legal battles over reproductive healthcare, especially following the 2022 Supreme Court decision that overturned Roe v. Wade. Since then, many states have imposed severe abortion restrictions, increasing reliance on medication abortion as an alternative.
Mifepristone, used in combination with misoprostol, accounts for roughly two-thirds of all abortions in the U.S. and is approved for use during the first 10 weeks of pregnancy. In 2023, the U.S. Food and Drug Administration (FDA) removed the requirement for in-person dispensing, allowing telehealth prescriptions and mail delivery after determining the drug is safe and effective.
However, Louisiana and other Republican-led states have challenged the FDA’s regulatory authority, citing potential health risks such as severe bleeding and infection. The appeals court sided with Louisiana, stating the state is likely to succeed in its legal challenge, prompting immediate action from drug manufacturers.
Danco warned that the decision creates confusion for patients and providers, disrupting time-sensitive medical care. GenBioPro emphasized the importance of maintaining access to safe, evidence-based healthcare and raised concerns about political interference in FDA oversight.
The Supreme Court previously declined a similar case in 2024 due to lack of legal standing, but new challenges led by states including Missouri, Kansas, and Idaho are still pending. As legal battles intensify, the outcome of this case could have far-reaching implications for abortion access and pharmaceutical regulation in the U.S.
